March 04, 2024

DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada

February 07, 2024

DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

November 13, 2023

DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update

November 09, 2023

DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update

November 07, 2023

DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality

September 07, 2023

DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

August 31, 2023

DURECT Corporation Announces Presentations in Upcoming Investor Conferences

August 09, 2023

DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update

August 03, 2023

DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business Update

July 20, 2023

DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

June 07, 2023

DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

May 08, 2023

DURECT Corporation Reports First Quarter 2023 Financial Results and Business Update

May 01, 2023

DURECT Corporation to Announce First Quarter 2023 Financial Results and Provide Business Update on May 8

April 27, 2023

DURECT Corporation to Host KOL Event on Alcohol-Associated Hepatitis

April 25, 2023

DURECT Corporation to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference

April 10, 2023

DURECT Announces Peer-Reviewed Article Accepted for Publication with Additional Data from Previously Completed Phase 2a Study of Larsucosterol in Alcohol-Associated Hepatitis

March 21, 2023

DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board

March 09, 2023

DURECT Corporation Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference

March 07, 2023

DURECT Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and AHFIRM Trial Update

February 28, 2023

DURECT Corporation to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 7

February 03, 2023

DURECT Corporation Announces $10 Million Registered Direct Offering of Common Stock and Warrants

November 28, 2022

DURECT Announces 1-for-10 Reverse Stock Split

November 02, 2022

DURECT Corporation Reports Third Quarter 2022 Financial Results and Update of Programs

October 26, 2022

DURECT Corporation to Announce Third Quarter 2022 Financial Results and Provide Business Update on November 2

October 06, 2022

DURECT Reaches Enrollment Milestone in Phase 2b AHFIRM Trial

September 26, 2022

Innocoll and DURECT Announce U.S. launch of POSIMIR®

September 06, 2022

DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference

August 04, 2022

DURECT Corporation Reports Second Quarter 2022 Financial Results and Update of Programs

July 27, 2022

DURECT Corporation to Announce Second Quarter 2022 Financial Results and Provide Business Update on August 4

July 05, 2022

DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer

May 18, 2022

DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference

May 04, 2022

DURECT Corporation Reports First Quarter 2022 Financial Results and Update of Programs

April 27, 2022

DURECT Corporation to Announce First Quarter 2022 Financial Results and Provide Business Update on May 4

March 23, 2022

DURECT Corporation To Present at the 2022 Cantor Fitzgerald Virtual Rare Orphan Disease Summit

March 09, 2022

DURECT Corporation Fireside Chat at the Oppenheimer 32nd Annual Healthcare Conference

March 07, 2022

DURECT Corporation Reports Fourth Quarter and Full Year 2021 Financial Results and Update of Programs

March 01, 2022

DURECT Corporation Doses First European Patient in Phase 2b AHFIRM Study of Larsucosterol(DUR-928) in Severe Alcohol-Associated Hepatitis

February 28, 2022

DURECT Corporation to Announce Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on March 7

January 06, 2022

DURECT Corporation to Participate in H.C. Wainwright Bioconnect Conference

December 22, 2021

DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR® (Bupivacaine Solution)

December 14, 2021

DURECT Corporation Expands Board of Directors with Appointment of Biopharmaceutical Industry Finance Veteran Peter Garcia

November 29, 2021

DURECT Corporation to Participate in Alcoholic Liver Disease Workshop Today at the 5th Annual NASH Summit

November 12, 2021

Data Presentation Today at The Liver Meeting® 2021 Shows Increasing Hospital Admissions for Alcohol-Associated Hepatitis (AH) in the U.S.

November 10, 2021

DURECT Corporation Doses First ex-U.S. Patient in Phase 2b AHFIRM Study of Larsucosterol (DUR-928) in Severe Alcohol-Associated Hepatitis

November 08, 2021

DURECT Corporation Announces Poster Presentation on the Prevalence of Hospitalized Alcohol-Associated Hepatitis (AH) Patients in the U.S. to be Presented at The Liver Meeting® 2021

November 02, 2021

DURECT Corporation Reports Third Quarter 2021 Financial Results and Update of Programs

October 26, 2021

DURECT Corporation to Announce Third Quarter 2021 Financial Results and Provide Business Update on November 2

October 07, 2021

DURECT Corporation Fireside Chat at the H.C. Wainwright 5th Annual NASH Investor Conference

September 23, 2021

DURECT Corporation Fireside Chat at the Cantor Fitzgerald Global Healthcare Conference 2021

September 15, 2021

DURECT Corporation Fireside Chat at Oppenheimer's Fall Healthcare Life Sciences & MedTech Summit